WealthOne’s Regeneron Pharmaceuticals REGN Stock Holding History

WealthOne’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$216K	Sell	263 -38	-13%	-$29.9K	0.09%	76
2023 Q2	$216K	Buy	301 +4	+1%	+$3.08K	0.08%	101
2023 Q1	$244K	Hold	297	–	–	0.1%	92
2022 Q4	$214K	Buy	+297	New	+$219K	0.09%	109
2022 Q2	–	Sell	-313	Closed	-$219K	–	134
2022 Q1	$219K	Sell	313 -31	-9%	-$19.6K	0.08%	113
2021 Q4	$217K	Buy	344 +7	+2%	+$4.3K	0.07%	104
2021 Q3	$204K	Buy	+337	New	+$209K	0.08%	127
2020 Q3	–	Sell	-330	Closed	-$206K	–	106
2020 Q2	$206K	Buy	+330	New	+$187K	0.13%	93
2019 Q1	–	Sell	-90	Closed	-$33K	–	434
2018 Q4	$33K	Buy	+90	New	+$32.9K	0.03%	211

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

WealthOne's REGN Position: Q3 2023 in Review

WealthOne reduced its Regeneron Pharmaceuticals (REGN) stake by 13% in Q3 2023, selling an estimated $29.9K and leaving 263 shares worth $216K. The position accounts for 0.09% of the portfolio, ranked #76.

WealthOne first reported a position in REGN in Q4 2018 and has held it in 9 quarters since. The position peaked at $244K in Q1 2023. 1,177 funds tracked by Wall St. Rank hold REGN as of Q3 2023.

WealthOne held 263 shares of Regeneron Pharmaceuticals worth $216K as of Q3 2023.
WealthOne sold 38 Regeneron Pharmaceuticals shares in Q3 2023, an estimated $29.9K.
Regeneron Pharmaceuticals made up 0.09% of WealthOne's portfolio in Q3 2023, its #76 holding.
WealthOne first reported a position in Regeneron Pharmaceuticals in Q4 2018 and has held it in 9 quarters since.
WealthOne's Regeneron Pharmaceuticals position peaked at $244K in Q1 2023.
1,177 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2023.

Based on WealthOne's 13F filing for Q3 2023, filed 12 Oct 2023.